Bioasis Technologies Inc.
BTI
주식 순위
#39864
Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused... Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused on innovating diagnostic methods and therapeutic solutions for a range of neurological conditions. The company's primary technological asset is the xB3 platform, engineered to enable the transport of medicinal compounds across the often-impenetrable blood-brain barrier. This capability is crucial for addressing central nervous system disorders, including various brain cancers, metabolic dysfunctions, and neurodegenerative illnesses. Bioasis is actively advancing its in-house pipeline with programs such as xB3-001 for brain metastases, xB3-002 for glioblastoma, and xB3-007 for neurodegenerative diseases, all designed to offer both symptomatic relief and disease-modifying benefits. The company has also established numerous strategic alliances. These include a partnership with Aposense Limited to deliver siRNA therapeutics for CNS disorders; a collaboration with Oxyrane UK Ltd. to combine the xB3 technology with Oxyrane's OxyCAT platform for enhanced enzyme replacement therapy targeting the brain; an agreement with Janssen Biotech, Inc. for the discovery, development, and commercialization of novel products leveraging the xB3 platform; and a research and licensing deal with Neuramedy Co Ltd. to develop and market an xB3-enhanced version of their antibody, Tomaralimab. Founded in 2006, Bioasis Technologies Inc. is headquartered in New Haven, Connecticut.
주가
$0.00366968
마지막 동기화: 2024-07-23
시가총액
$291.42K
변동 (1일)
-0.81%
변동 (1년)
1,734.84%
국가
US
거래 Bioasis Technologies Inc. (BTI)
카테고리
Healthcare
의 시가총액 Bioasis Technologies Inc.(BTI)
시가총액: $291.42K
October 2026 기준으로 Bioasis Technologies Inc.의 시가총액은 $291.42K입니다. 이는 당사 데이터에 따르면 Bioasis Technologies Inc.이 세계에서 39864th번째로 가치 있는 기업임을 의미합니다. 시가총액은 상장된 회사의 발행 주식 총 시장 가치를 의미하며, 일반적으로 회사의 가치를 측정하는 데 사용됩니다.
2010부터 2026까지 Bioasis Technologies Inc.의 시가총액 기록
BTI 가장 인기있는 상위 5 가지 stocks과 비교하여
